SCHEMBL24434909

SCHEMBL24434909

CC1CC(O)CN1c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
SLC18A3 Q16572 1/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 2/20 0.40
ALOX5 P09917 1/20 0.40
ALDH1A1 P00352 2/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
PIK3CD O00329 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
G6PD P11413 1/20 0.37
SIGMAR1 Q99720 1/20 0.36
BACE1 P56817 2/20 0.35
RIPK1 Q13546 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6385406 0.81 GFER (0.35) MEN1KMT2ASLC18A3MAPK1SMN1; SMN2
SCHEMBL16480433 0.81 CNR1 (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL1071244 0.81 MAPK1 (0.50) SLC18A3MAPK1SMN1; SMN2MAPTALOX5
SCHEMBL24434975 0.77 PIK3CD (0.55) MEN1KMT2ASLC18A3MAPK1ALOX5
SCHEMBL2899074 0.74 MEN1 (0.50) MEN1KMT2APIK3CDL3MBTL1KDM4E
SCHEMBL17458687 0.73 MAPK1 (0.45) SLC18A3MAPK1SMN1; SMN2MAPTALOX5
SCHEMBL4019885 0.72 SLC18A3 (0.42) MEN1KMT2ASLC18A3MAPK1SMN1; SMN2
SCHEMBL3245667 0.72 RAD52 (0.40) MEN1KMT2AMAPTALDH1A1POLB
SCHEMBL13380438 0.71 MAPK1 (0.50) SLC18A3MAPK1SMN1; SMN2MAPTALOX5
SCHEMBL21535460 0.69 MAPK1 (0.39) SLC18A3MAPK1SMN1; SMN2MAPTALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G MEN1 1347/4885KMT2A 4802/4885SLC18A3 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.